|
||||||||||
 |
Dendreon: The Revenge of ProvengeTue Apr 14th, 2009
David Miller When Dendreon (DNDN) halted trading last night and announced it was going to release the results of its IMPACT Phase III trial of Provenge for late-stage prostate cancer, the butterflies started |
LIFE & MONEY AUDIO & VIDEO FAMILY & FINANCE SUBSCRIPTIONS & PRODUCTS OPTIONSMITH BY STEVE SMITH BUZZ & BANTER JEFF COOPER'S DAILY MARKET REPORT FLEXFOLIO HOOFY & BOO 5 THINGS RANDOM THOUGHTS UMV MINYANLAND EMAIL ALERTS MV EXCHANGE ARCHIVES THE WEEK'S ARTICLES DICTIONARY PROFESSORS 
